1006877-41-3
1006877-41-3 structure
- Name: Sifalimumab
- Chemical Name: Sifalimumab
- CAS Number: 1006877-41-3
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2022-11-13 23:42:56
- Modify Date: 2025-10-29 19:01:14
-
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
| Name | Sifalimumab |
|---|
| Description | Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2]. Cell Viability Assay[2] Cell Line: U-87MG cells and AGS lymphocytes Concentration: 3-36 μg/well Incubation Time: 72 hours Result: Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05). |
| In Vivo | Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2]. Animal Model: Wild-type male BALB/c mice[2] Dosage: 30 mg/kg and 3 μg/g Administration: Subcutaneous injection; 30 mg/kg and 3 μg/g Result: Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05). |
| References |
| No Any Chemical & Physical Properties |